Login
$AGEN
$6.35 +$0.06 (0.95%) After hours

$AGEN 8-K/A SEC Filings

Filed On Filing
08 Nov 2024 8-K/A: Departure/Election of Directors or Officers; Compensation

On August 8, 2024, Agenus Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) to disclose the appointment of Thomas L. Harrison to the Company’s Board of Directors (the “Board”). At the time of filing, the Boa...

11 Sep 2015 8-K/A: Financial Statements and Exhibits

The Note Purchase Agreement is not intended to provide any factual information about the Company. The Note Purchase Agreement contains representations, warranties and covenants that the Company and Oberland made to each other as of speci...

29 Apr 2014 8-K/A: Financial Statements and Exhibits

We have audited the accompanying financial statements of 4-Antibody AG, which comprise the statement of financial position as of 31 December 2013 and 2012, and the related statements of comprehensive income, changes in equity and cash fl...

23 Oct 2012 8-K/A: Other Events

Agenus Commences Phase 2 Study of HerpV Vaccine for the Treatment of Genital Herpes

29 Jan 2001 8-K/A: Financial Statements and Exhibits

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, shareholders' equity and cash flows present fairly, in all material respects, the financial position of Aquila Biopharmac...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support